These findings are consistent with those of previous studies showing that patients who have MPN with type 1-like CALR mutation are associated with a myelofibrosis phenotype and those with type 2-like mutation are mainly associated with an ET phenotype [6,9]. The gene discussed is CALR; the disease is myeloproliferative neoplasm.